Early Olezarsen Results Show 50% Reduction in Triglycerides

A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.

Related Keywords

Boston , Massachusetts , United States , North Carolina , Philadelphia , Pennsylvania , America , Daniel Soffer , Brian Bergmark , Nehaj Pagidipati , National Lipid Association , American College Of Cardiology , Duke Clinical Research Institute , Duke School Of Medicine , American College , Scientific Session , New England , Major Subgroup Failed , North America , Penn Medicine , National Lipid , Duke School , Lipids , Ipid Management , Cv Risk , Cardiovascular Risk , V Risk Factors , Cardiovascular Risk Factors , Cardiovascular Risk Management , Triglycerides , Hypertriglyceridemia Hypertriglyceridaemia , Aminotransferase , Dust , Liver Enzymes , Liver Studies , Olt , Ransaminase , Vldl Cholesterol , Low Density Lipoprotein Cholesterol , High Density Lipoprotein Cholesterol , Fdl C , Dl , Lipoproteins ,